SGX Presents Preclinical MET Data at AACR
April 15 2008 - 5:00PM
PR Newswire (US)
SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- SGX Pharmaceuticals,
Inc. (NASDAQ:SGXP) presented abstract #4844 at the 2008 Annual
Meeting of the American Association for Cancer Research (AACR) in
San Diego. The poster entitled "SGX523, a potent and exquisitely
selective inhibitor of the HGF receptor tyrosine kinase (MET),
inhibits growth of human glioblastoma tumors in a mouse model," was
presented in the afternoon poster session entitled Small Molecule
Kinase Inhibitors 1 in Exhibit Hall B-F. SGX's MET program
comprises potent, selective ATP-competitive MET inhibitors, from
which a number of drug-like compounds have been identified. The
first development candidate, SGX523, demonstrated potent anti-tumor
activity when dosed orally in various mouse models of human cancer
including glioblastoma, gastric cancer and lung cancer. SGX's
second development candidate, SGX126, is structurally distinct and
may possess several advantages over SGX523, including the potential
for a lower human dose. "We are continuing to progress SGX126
towards IND submission, while evaluating additional follow-on
compounds for our MET program," said Mike Grey, the CEO of SGX
Pharmaceuticals. About SGX Pharmaceuticals SGX Pharmaceuticals,
Inc. is a biotechnology company focused on the discovery,
development and commercialization of novel, targeted therapeutics
directed at addressing unmet medical needs in oncology. Our drug
development programs target the MET receptor tyrosine kinase, an
enzyme implicated in a broad array of cancers, and the BCR-ABL
tyrosine kinase enzyme for the treatment of Chronic Myelogenous
Leukemia, or CML. Our drug discovery activities are focused on a
portfolio of other protein and enzyme targets that have been
implicated in human cancers including JAK2 and RAS. More
information on the pipeline and drug discovery platform can be
found at http://www.sgxpharma.com/ and in the Company's various
filings with the Securities and Exchange Commission. Forward
Looking Statements Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements include, but are not limited to, statements related to
the Company's MET program and the advancement of the Company's drug
development and discovery pipeline. These statements are only
predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug discovery, development and
commercialization, which include, without limitation, the potential
failure of development candidates to advance through preclinical
studies or demonstrate safety and efficacy in clinical testing and
the ability to file INDs in the referenced time frames. The results
of early preclinical studies or clinical trials may not be
predictive of future results, and the Company cannot provide any
assurances that any of its compounds or development candidates will
have favorable results in preclinical studies or clinical trials.
For a discussion of these and other factors, please refer to the
risk factors described in the Company's annual report on Form 10-K
for the year ended December 31, 2007, as well as other filings with
the Securities and Exchange Commission. You are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date hereof. This caution is made under the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. All forward-looking statements are qualified in their
entirety by this cautionary statement and SGX undertakes no
obligation to revise or update this press release to reflect events
or circumstances after the date hereof. DATASOURCE: SGX
Pharmaceuticals, Inc. CONTACT: Bonnie Feldman, Sr. Director,
Investor Relations of SGX Pharmaceuticals, +1-858-344-8860 Web
site: http://www.sgxpharma.com/
Copyright
Sgx Pharmaceuticals (MM) (NASDAQ:SGXP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sgx Pharmaceuticals (MM) (NASDAQ:SGXP)
Historical Stock Chart
From Aug 2023 to Aug 2024